数据中心
龙虎榜
大单追踪
资金流向
业绩预告
新股申购
行情中心
沪深市场
香港市场
美国市场
全球市场
行业风云
全球市场
向上 向下

董事介绍

注:董事持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
周峰 Chief Executive Officer and Director 30 5.00万美元 10.63 2022-07-18
郑军 Director 45 未披露 未持股 2022-07-18
Tong Liu Independent Director 43 未披露 未持股 2022-07-18
Songfan He Independent Director 49 未披露 未持股 2022-07-18
Xiaodong Ji Independent Director 52 未披露 未持股 2022-07-18

高管介绍

注:高管持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
周峰 Chief Executive Officer and Director 30 5.00万美元 10.63 2022-07-18
Xiaodong Pan Chief Financial Officer 44 0.83万美元 未持股 2022-07-18

董事简历

中英对照 |  中文 |  英文
周峰

周峰,他曾担任China sst Pharmaceuticals, Inc.自2017年7月4日起担任首席执行官和董事。他曾担任Taizhou Suxuantang, China Sxt Pharmaceuticals, Inc. 首席执行官。2015年1月至2017年5月任Taizhou Suxuantang 副经理。作为Taizhou Suxuantang 的副经理,他负责采购,并制定具有成本效益的采购策略。 Zhou 先生毕业于解放军后勤工程大学工商管理专业。


Feng Zhou has been China Sxt Pharmaceuticals, Inc. CEO and director since July 4 2017. He was the CEO of Taizhou Suxuantang, China Sxt Pharmaceuticals, Inc. VIE Entity from May 2017 to February, 2018. From January 2015 to May 2017 he was the vice manager of Taizhou Suxuantang. As vice manager of Taizhou Suxuantang, he was responsible for procurement and formulating a cost effective strategy for purchasing goods and services. Mr. Zhou graduated from Logistical Engineering University of PLA and majored in Business Administration.
周峰,他曾担任China sst Pharmaceuticals, Inc.自2017年7月4日起担任首席执行官和董事。他曾担任Taizhou Suxuantang, China Sxt Pharmaceuticals, Inc. 首席执行官。2015年1月至2017年5月任Taizhou Suxuantang 副经理。作为Taizhou Suxuantang 的副经理,他负责采购,并制定具有成本效益的采购策略。 Zhou 先生毕业于解放军后勤工程大学工商管理专业。
Feng Zhou has been China Sxt Pharmaceuticals, Inc. CEO and director since July 4 2017. He was the CEO of Taizhou Suxuantang, China Sxt Pharmaceuticals, Inc. VIE Entity from May 2017 to February, 2018. From January 2015 to May 2017 he was the vice manager of Taizhou Suxuantang. As vice manager of Taizhou Suxuantang, he was responsible for procurement and formulating a cost effective strategy for purchasing goods and services. Mr. Zhou graduated from Logistical Engineering University of PLA and majored in Business Administration.
郑军

郑军于2018年12月31日被任命为公司董事。郑先生从1999年至2004年曾任江西博世达制药有限公司销售区域经理,以及台州九天药业有限公司部门经理和副总经理。郑先生于2005年至2012年间担任总经理。郑先生于2013年至2015年间担任台州仁济中药饮片有限公司总经理,并于2016年起担任江苏健康药业投资管理有限公司总经理。 到2017年。郑先生现为台州素悬堂副总裁。 郑先生于1999年在江南大学无锡轻工业大学获得学士学位。


Jun Zheng has been appointed as China Sxt Pharmaceuticals, Inc. director upon closing of China Sxt Pharmaceuticals, Inc. IPO on December 31 2018. Mr. Zheng was a sales area manager at Jiangxi Bo Shi Da Pharmaceutical Co., Ltd. from 1999 to 2004 and a department manager and deputy general manager at Taizhou Jiutian Pharmaceutical Co., Ltd. from the 2005 to 2012. Mr. Zheng served as a general manager at Taizhou Renji Chinese Traditional Medicine Pieces Co., Ltd. from 2013 to 2015 and a general manager at Jiangsu Health Pharmaceutical Investment Management Co., Ltd. from 2016 to 2017. Currently, Mr. Zheng is a vice president at Taizhou Suxuantang. Mr. Zheng received his bachelor's degree from Jiangnan University Wuxi Light Industry University in 1999.
郑军于2018年12月31日被任命为公司董事。郑先生从1999年至2004年曾任江西博世达制药有限公司销售区域经理,以及台州九天药业有限公司部门经理和副总经理。郑先生于2005年至2012年间担任总经理。郑先生于2013年至2015年间担任台州仁济中药饮片有限公司总经理,并于2016年起担任江苏健康药业投资管理有限公司总经理。 到2017年。郑先生现为台州素悬堂副总裁。 郑先生于1999年在江南大学无锡轻工业大学获得学士学位。
Jun Zheng has been appointed as China Sxt Pharmaceuticals, Inc. director upon closing of China Sxt Pharmaceuticals, Inc. IPO on December 31 2018. Mr. Zheng was a sales area manager at Jiangxi Bo Shi Da Pharmaceutical Co., Ltd. from 1999 to 2004 and a department manager and deputy general manager at Taizhou Jiutian Pharmaceutical Co., Ltd. from the 2005 to 2012. Mr. Zheng served as a general manager at Taizhou Renji Chinese Traditional Medicine Pieces Co., Ltd. from 2013 to 2015 and a general manager at Jiangsu Health Pharmaceutical Investment Management Co., Ltd. from 2016 to 2017. Currently, Mr. Zheng is a vice president at Taizhou Suxuantang. Mr. Zheng received his bachelor's degree from Jiangnan University Wuxi Light Industry University in 1999.
Tong Liu

Tong Liu,2019年12月起任职于北京盈科泰州律师事务所。2016年6月至2019年11月任职于江苏普臣律师事务所。 2014年10月至2016年6月就职于江苏碧宏律师事务所。 2010年12月至2014年10月在江苏苏益律师事务所工作。 2006年9月至2010年12月在江苏朱氏律师事务所工作。 Liu先生于2002年获得南京大学法学学士学位。


Tong Liu was appointed as China Sxt Pharmaceuticals, Inc. independent director on May 10 2022. He has worked at Beijing Yingke Taizhou Law Firm since December 2019. From June 2016 to November 2019 he worked at Jiangsu Puchen Law Firm. From October 2014 to June 2016 he worked at Jiangsu Bihong Law Firm. From December 2010 to October 2014 he worked Jiangsu Suyi Law Firm. From September 2006 to December 2010 he worked at Jiangsu Zhushi law firm. Mr. Liu obtained his Bachelor of Law degree from Nanjing University in 2002.
Tong Liu,2019年12月起任职于北京盈科泰州律师事务所。2016年6月至2019年11月任职于江苏普臣律师事务所。 2014年10月至2016年6月就职于江苏碧宏律师事务所。 2010年12月至2014年10月在江苏苏益律师事务所工作。 2006年9月至2010年12月在江苏朱氏律师事务所工作。 Liu先生于2002年获得南京大学法学学士学位。
Tong Liu was appointed as China Sxt Pharmaceuticals, Inc. independent director on May 10 2022. He has worked at Beijing Yingke Taizhou Law Firm since December 2019. From June 2016 to November 2019 he worked at Jiangsu Puchen Law Firm. From October 2014 to June 2016 he worked at Jiangsu Bihong Law Firm. From December 2010 to October 2014 he worked Jiangsu Suyi Law Firm. From September 2006 to December 2010 he worked at Jiangsu Zhushi law firm. Mr. Liu obtained his Bachelor of Law degree from Nanjing University in 2002.
Songfan He

Songfan He,2017年至今在北京启通国际中医药科学研究所工作,曾任《国家公务员健康指南》编委。 1996年8月至2003年12月在信宜市第五人民医院工作。 He先生1996年毕业于徐州医学院临床医学专业,2011年毕业于中国烟台中医学院临床医学专业。


Songfan He was appointed as China Sxt Pharmaceuticals, Inc. independent director on May 10 2022. He has worked at Beijing Qitong International Institute of Traditional Chinese Medicine Science since 2017. He has served as the director of editorial board of "National Civil Servants' Health Guide". From August 1996 to December 2003 he worked at Fifth People's Hospital of Xinyi City. Mr. He graduated from Xuzhou Medical College in Clinical Medicine in 1996 graduated from China Yantai College of Traditional Chinese Medicine in Clinical Medicine in 2011.
Songfan He,2017年至今在北京启通国际中医药科学研究所工作,曾任《国家公务员健康指南》编委。 1996年8月至2003年12月在信宜市第五人民医院工作。 He先生1996年毕业于徐州医学院临床医学专业,2011年毕业于中国烟台中医学院临床医学专业。
Songfan He was appointed as China Sxt Pharmaceuticals, Inc. independent director on May 10 2022. He has worked at Beijing Qitong International Institute of Traditional Chinese Medicine Science since 2017. He has served as the director of editorial board of "National Civil Servants' Health Guide". From August 1996 to December 2003 he worked at Fifth People's Hospital of Xinyi City. Mr. He graduated from Xuzhou Medical College in Clinical Medicine in 1996 graduated from China Yantai College of Traditional Chinese Medicine in Clinical Medicine in 2011.
Xiaodong Ji

Xiaodong Ji于2019年10月成立Jiangsu Sutaitang E-Commerce Co., Ltd.,现任SutaitangCEO。他还是江苏健康药业投资有限公司的副总经理。他在企业管理,品牌链运营和市场营销方面拥有二十年的丰富经验。加入中国苏轩堂药业有限公司之前,他分别担任过东方紫酒,正德药业,中国一带购物商城有限公司(中宗投集团的子公司,“购物商城”)的首席执行官。他负责东方紫酒和正德药业的企业管理和渠道建设。东方紫酒创造了中国第五大葡萄酒类别-紫葡萄酒。正德药业是由吉林紫鑫药业股份有限公司控制的品牌渠道企业,吉林紫鑫药业股份有限公司在深圳证券交易所上市。他负责购物中心的战略规划和生态链建设,这是“一带一路”倡议下的世界购物中心体系。他拥有北京中医药大学的学士学位。


Xiaodong Ji was appointed as China Sxt Pharmaceuticals, Inc. director on May 22 2021. Mr. Ji established Jiangsu Sutaitang E-Commerce Co., Ltd. “Sutaitang” in October 2019 and currently serves as the CEO of Sutaitang. He is also the deputy general manager of Jiangsu Health Pharmaceutical investment Co., Ltd. Mr. Ji has rich experience of two decades in corporation management, brand chain operation and marketing. Prior to joining China Sxt Pharmaceuticals, Inc., Mr. Ji has served as CEOs of Dongfang Purple Wine, Zhengde Pharmaceutical, China Belt and Road Shopping Mall Co., Ltd. (the subsidiary of Zhong Zong Tou Group, “Shopping Mall”), respectively. Mr. Ji was responsible for the enterprise management and channel construction of Dongfang Purple Wine and Zhengde Pharmaceutical. Dongfang Purple Wine creates the fifth largest category of wine in China - Purple wine (purple wine is a fine wine made from mulberry fruit). Zhengde pharmaceutical is a brand channel enterprise controlled by Jilin Zixin Pharmaceutical Industrial Co., Ltd. which is listed on Shenzhen Stock Exchange. Mr. Ji was in charge of the strategic planning and ecological chain construction of Shopping Mall, which is a world shopping mall system under the Belt and Road Initiative. Mr. Ji earned his bachelor degree from Beijing University of Chinese Medicine.
Xiaodong Ji于2019年10月成立Jiangsu Sutaitang E-Commerce Co., Ltd.,现任SutaitangCEO。他还是江苏健康药业投资有限公司的副总经理。他在企业管理,品牌链运营和市场营销方面拥有二十年的丰富经验。加入中国苏轩堂药业有限公司之前,他分别担任过东方紫酒,正德药业,中国一带购物商城有限公司(中宗投集团的子公司,“购物商城”)的首席执行官。他负责东方紫酒和正德药业的企业管理和渠道建设。东方紫酒创造了中国第五大葡萄酒类别-紫葡萄酒。正德药业是由吉林紫鑫药业股份有限公司控制的品牌渠道企业,吉林紫鑫药业股份有限公司在深圳证券交易所上市。他负责购物中心的战略规划和生态链建设,这是“一带一路”倡议下的世界购物中心体系。他拥有北京中医药大学的学士学位。
Xiaodong Ji was appointed as China Sxt Pharmaceuticals, Inc. director on May 22 2021. Mr. Ji established Jiangsu Sutaitang E-Commerce Co., Ltd. “Sutaitang” in October 2019 and currently serves as the CEO of Sutaitang. He is also the deputy general manager of Jiangsu Health Pharmaceutical investment Co., Ltd. Mr. Ji has rich experience of two decades in corporation management, brand chain operation and marketing. Prior to joining China Sxt Pharmaceuticals, Inc., Mr. Ji has served as CEOs of Dongfang Purple Wine, Zhengde Pharmaceutical, China Belt and Road Shopping Mall Co., Ltd. (the subsidiary of Zhong Zong Tou Group, “Shopping Mall”), respectively. Mr. Ji was responsible for the enterprise management and channel construction of Dongfang Purple Wine and Zhengde Pharmaceutical. Dongfang Purple Wine creates the fifth largest category of wine in China - Purple wine (purple wine is a fine wine made from mulberry fruit). Zhengde pharmaceutical is a brand channel enterprise controlled by Jilin Zixin Pharmaceutical Industrial Co., Ltd. which is listed on Shenzhen Stock Exchange. Mr. Ji was in charge of the strategic planning and ecological chain construction of Shopping Mall, which is a world shopping mall system under the Belt and Road Initiative. Mr. Ji earned his bachelor degree from Beijing University of Chinese Medicine.

高管简历

中英对照 |  中文 |  英文
周峰

周峰,他曾担任China sst Pharmaceuticals, Inc.自2017年7月4日起担任首席执行官和董事。他曾担任Taizhou Suxuantang, China Sxt Pharmaceuticals, Inc. 首席执行官。2015年1月至2017年5月任Taizhou Suxuantang 副经理。作为Taizhou Suxuantang 的副经理,他负责采购,并制定具有成本效益的采购策略。 Zhou 先生毕业于解放军后勤工程大学工商管理专业。


Feng Zhou has been China Sxt Pharmaceuticals, Inc. CEO and director since July 4 2017. He was the CEO of Taizhou Suxuantang, China Sxt Pharmaceuticals, Inc. VIE Entity from May 2017 to February, 2018. From January 2015 to May 2017 he was the vice manager of Taizhou Suxuantang. As vice manager of Taizhou Suxuantang, he was responsible for procurement and formulating a cost effective strategy for purchasing goods and services. Mr. Zhou graduated from Logistical Engineering University of PLA and majored in Business Administration.
周峰,他曾担任China sst Pharmaceuticals, Inc.自2017年7月4日起担任首席执行官和董事。他曾担任Taizhou Suxuantang, China Sxt Pharmaceuticals, Inc. 首席执行官。2015年1月至2017年5月任Taizhou Suxuantang 副经理。作为Taizhou Suxuantang 的副经理,他负责采购,并制定具有成本效益的采购策略。 Zhou 先生毕业于解放军后勤工程大学工商管理专业。
Feng Zhou has been China Sxt Pharmaceuticals, Inc. CEO and director since July 4 2017. He was the CEO of Taizhou Suxuantang, China Sxt Pharmaceuticals, Inc. VIE Entity from May 2017 to February, 2018. From January 2015 to May 2017 he was the vice manager of Taizhou Suxuantang. As vice manager of Taizhou Suxuantang, he was responsible for procurement and formulating a cost effective strategy for purchasing goods and services. Mr. Zhou graduated from Logistical Engineering University of PLA and majored in Business Administration.
Xiaodong Pan

Xiaodong Pan, 2015年3月以来,他担任Jiangsu Suxuantang Pharmaceutical Co., Ltd.(公司在中国的合并可变利益实体)的财务总监。在此之前,他于2007年1月至2015年3月担任泰州杰达混凝土有限公司的财务总监。他于2000年获得南京经济学院会计学士学位,并于2021年获得南京理工大学工商管理硕士学位。


Xiaodong Pan was appointed as China Sxt Pharmaceuticals, Inc. Chief Financial Officer on January 31 2022. He has served as the Finance Director of Jiangsu Suxuantang Pharmaceutical Co., Ltd., the consolidated variable interests entity of the Company in China, since March 2015. Prior to that, Mr. Pan was the Financial Director of Taizhou Jieda Concrete Co., Ltd. from January 2007 to March 2015. Mr. Pan earned his Bachelor's Degree in Accounting from Nanjing College of Economics in 2000 and obtained his Master's Degree in Business Administration in 2021 from Nanjing Institute of Technology.
Xiaodong Pan, 2015年3月以来,他担任Jiangsu Suxuantang Pharmaceutical Co., Ltd.(公司在中国的合并可变利益实体)的财务总监。在此之前,他于2007年1月至2015年3月担任泰州杰达混凝土有限公司的财务总监。他于2000年获得南京经济学院会计学士学位,并于2021年获得南京理工大学工商管理硕士学位。
Xiaodong Pan was appointed as China Sxt Pharmaceuticals, Inc. Chief Financial Officer on January 31 2022. He has served as the Finance Director of Jiangsu Suxuantang Pharmaceutical Co., Ltd., the consolidated variable interests entity of the Company in China, since March 2015. Prior to that, Mr. Pan was the Financial Director of Taizhou Jieda Concrete Co., Ltd. from January 2007 to March 2015. Mr. Pan earned his Bachelor's Degree in Accounting from Nanjing College of Economics in 2000 and obtained his Master's Degree in Business Administration in 2021 from Nanjing Institute of Technology.